Abstract
Positron emission tomography (PET) using radiotracers with high molecular specificity is an important scientific tool in studies of monoamine oxidase (MAO), an important enzyme in the regulation of the neurotransmitters dopamine, norepinephrine, and serotonin as well as the dietary amine, tyramine. MAO occurs in two different subtypes, MAO A and MAO B, which have different substrate and inhibitor specificity and which are different gene products. The highly variable subtype distribution with different species makes human studies of special value. MAO A and B can be imaged in the human brain and certain peripheral organs using PET and carbon-11 (half-life 20.4 minutes) labeled mechanism-based irreversible inhibitors, clorgyline and l-deprenyl, respectively. In this article we introduce MAO and describe the development of these radiotracers and their translation from preclinical studies to the investigation of variables affecting MAO in the human brain and peripheral organs.
Similar content being viewed by others
Reference
Hare MLC (1928) Tyramine oxidase. I. A new enzyme system in liver. Biochem J 22:968–979
Shih JC, Chen K, Ridd MJ (1999) Monoamine oxidase: From genes to behavior. Ann Rev Neurosci 22:197–217
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285–1297
Knoll J, Magyar K (1972) Some puzzling effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5:393–408
Youdim MDH, Riederer P (1993) Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm 91:181–195
Inoue H, Castagnoli K, Van Der Schyf C, Mabic S, Igarashi K, Castagnoli N Jr. (1999) Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinyl derivatives. J Pharmacol Exp Ther 291:856–864
Saura J, Nadal E, van den Berg B et al. (1996) Localization of monoamine oxidases in human peripheral tissues. Life Sci 59:1341–1349
Cohen G, Kesler N (1999) Monoamine oxidase and mitochondrial respiration. J Neurochem 73:2310–2315
Vindis C, Seguelas MH, Lanier S et al. (2001) Dopamine induces ERK activation in renal tubule epithelial cells through H2O2 produced by monoamine oxidase. Kidney Int. 59:76–86
Pizzinat N, Copin N, Vindis C et al. (1999) Reactive oxygen species production by monoamine oxidases in intact cells. Naunyn-Schmiedeberg’s Arch Pharmacol 359:428–431
Caldecott-Hazard S, Schneider LS (1992) Clinical and biochemical aspects of depressive disorders. III. Treatment and controversies. Synapse 10:141–168
Selikoff I, Robitzek E, Ornstein G (1952) Treatment of pulmonary tuberculosis with hydrazide derivatives of isonicotinic acid. JAMA 150:973–980
Crane GE (1956) Psychiatric side effects of iproniazide. Am J Psychiatry 112:494–497
Zeller EA, Barsky J, Berman ER (1955) Amine oxidases. XI. Inhibition of monoamine oxidase by 1-isonicotinyl-2-isopropylhydrazine. J. Biol. Chem. 214:267–274
Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 122:509–522
Kopin I (1993) Monoamine oxidase (MAO). Relationship to foods, poisons, and medicines. Biogenic Amines 9:355–365
Birkmayer W, Riederer P (1984) Deprenyl prolongs the therapeutic efficacy of combined l-DOPA in Parkinson’s disease. Adv. Neurol. 40:475–481
Langston JW, Ballard JW, Tetrud JW et al. (1983) Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 219:979–980
Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245:519–522
Parkinson’s Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321:1364–1371
Parkinson’s Study Group (1996) Effect of lazabemide on the progression of disability in early Parkinson’s disease. Ann. Neurol. 40:99–107
Fowler JS, Volkow ND, Logan J et al. (1994) Slow recovery of human brain MAO B after l-deprenyl withdrawal. Synapse 18:86–93
Fowler JS, Fazzini E, Volkow ND (1996) Deprenyl and levodopa and Parkinson’s disease progression. Ann Neurol 40 267–268
Bach AWJ, Lan NC, Johnson DL (1988) cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc Natl Acad Sci U S A 85:4934–4938
Collins FA, Murphey DL, Reiss AR et al. (1992) Clinical, biochemical and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to microdeletion Xp11.3 including the Norrie disease locus and monoamine oxidase (MAO A and MAO B) genes. Am J Med Genet 42:127–134
Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA (1993) Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 262:578–80
Veenstra-Vander Weele J, Anderson GM, Cook EH Jr. (2000) Pharmacogenetics and the serotonin system: Initial studies and future directions. Eur. J. Pharmacol. 410:165–181
Cases O, Seif I, Grimsby J et al. (1995) Aggressive behavior and altered amounts of serotonin and norepinephrine in mice lacking MAO A. Science 268:1763–1766
Chen K, Holschneider DP, Wu W, Rebrin I, Shih JC (2004) A spontaneous point mutation produces monoamine oxidase A/B knock-out mice with greatly elevated monoamines and anxiety-like behavior. J Biol Chem 279:39645–39652
Shih JC, Thompson RF, (1999) Monoamine oxidase in neuropsychiatry and behavior. Am J Hum Genet 65:593–598
Whitaker-Azmitia PM, Zhang X, Clarke C (1994) Effects of gestational exposure to monoamine oxidase inhibitors in rats: Preliminary behavioral and neurochemical studies. Neuropsychopharmacology 11:125–132
Mejia JM, Ervin FR, Baker GB, Palmour RM (2002) Monoamine oxidase inhibition during brain development induces pathological aggressive behavior in mice. Biol Psychiatry 52:811–821
Sabol SZ, Hu S, Hamer D (1998) A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 103:273–279
Caspi A, Sugden K, Moffitt TE et al. (2003) Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 301:386–389
Chen K (2004) Organization of MAO A and MAO B promoters and regulation of gene expression. NeuroToxicology 25:31–36
Hamer D (2002) Genetics. Rethinking behavior genetics. Science 298:71–72
Fowler JS, MacGregor RR, Wolf AP et al. (1987) Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science 235:481–4857
Fowler JS, Logan J, Volkow ND, Wang GJ, MacGregor RR, Ding, YS (2002) Monoamine oxidase: Radiotracer development and human studies. Methods 27:263–277
Abeles RH, Maycock AL (1976) Suicide enzyme inactivators. Acc Chem Res 9:313–319
MacGregor RR, Fowler JS, Wolf AP (1988) Synthesis of suicide inhibitors of monoamine oxidase: Carbon-11 labeled clorgyline, l-deprenyl and d-deprenyl. J Label Compd Radiopharm 25:1–9
Fowler JS, Wolf AP, MacGregor RR et al. (1988) Mechanistic positron emission tomography studies demonstration of a deuterium isotope effect in the monoamine oxidase-catalyzed binding of [11C]l-deprenyl in living baboon brain. J Neurochem 51(5):1524–1534
Belleau B, Moran J (1963) Deuterium isotope effects in relation to the chemical mechanism of monoamine oxidase. Ann NY Acad Sci 107:822–839
Fowler JS, Wang GJ, Logan J et al. (1995) Selective reduction of radiotracer trapping by deuterium substitution: Comparison of carbon-11-l-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med 36:1255–1262
Fowler JS, Volkow ND, Logan J et al. (1993) Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson’s disease: The degree and reversibility of human brain MAO B inhibition by Ro 19 6327. Neurology 43:984–1992
Logan J, Fowler JS, Volkow ND et al. (2000) Reproducibility of repeated measures of deuterium substituted [11C]l-deprenyl (and [11C]l-deprenyl-D2) binding in the human brain. Nucl Med Biol 27:43–49
Logan J (2000) Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 27(7):661–670
Fowler JS, Volkow ND, Logan J et al. (2001) Evidence that l-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain. Life Sci 68:2759–2768
Fowler JS, Logan J, Ding YS et al. (2001) Non-MAO A binding of clorgyline in white matter in human brain. Neurochemistry 79:1039–1046
Fowler JS, Logan J, Wang, G-J et al. (2003) Monoamine oxidase A imaging in peripheral organs in healthy human subjects. Synapse 49:178–187
Fowler JS, Logan, J, Wang G-J et al. (2002) PET imaging of monoamine oxidase B in peripheral organs in humans. J Nucl Med 43:1331–1338
Fowler JS, Logan J, Wang G-J (2004) Comparison of the binding of the irreversible monoamine oxidase tracers, [(11)C]clorgyline and [(11)C]l-deprenyl in brain and peripheral organs in humans. Nucl Med Biol 31:313–319
Fowler JS, Volkow ND, Wang G-J et al. (1997) Age-related increases in brain MAO B in healthy human subjects. Neurobiol Aging 18:431–435
Fowler CJ, Wiberg A, Oreland L et al. (1980) The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49:1–20
Terry RD, DeTeresa R, Hansen LA (1987) Neocortical cell counts in normal human adult aging. Ann Neurol 21:530–539
Youdim MB, Bar Am O, Yogev-Falach M et al. (2005) Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79:172–179
Buchsbaum MS, Coursey, RD, Murphy DL (1976) The biochemical high-risk paradigm: Behavioral and familial correlates of low platelet monoamine oxidase activity. Science Oct 15;194(4262):334–339 Review
Fowler JS, Logan J, Wang GJ, Volkow ND (2003) Monoamine oxidase and cigarette smoking. NeuroToxicology 24(1):75–82 (Jan)Review
Oreland L, Fowler CJ, Schalling D (1981) Low platelet monoamine oxidase activity in cigarette smokers. Life Sci 29:2511–2518
Norman TR, Chamberlain KG, French MA (1987) Platelet monoamine oxidase: Low activity in cigarette smokers. Psychiatry Res 20:199–205 Mar
Berlin I, Said S, Spreux-Varocuax O et al. (1995) Monoamine oxidase A and B in heavy smokers. Biol Psychiatry 33:756–761
Fowler JS, Volkow ND, Wang G-J et al. (1996) Brain MAO A inhibition in cigarette smokers. Proc Natl Acad Sci U S A 93:14065–14069
Fowler JS, Wang G-J, Volkow ND et al. (1996) Inhibition of monoamine oxidase B in the brains of smokers. Nature 379:733–736
Fowler JS, Wang G-J, Volkow ND et al. (2000) Maintenance of brain monoamine oxidase B inhibition in smokers after overnight cigarette abstinence. Am J Psychiatry 157:1864–1866
Fowler JS, Volkow ND, Logan J et al. (1998) An acute dose of nicotine does not inhibit MAO B in baboon brain in vivo. Life Sci 63PL:19–23
Fowler JS, Wang G-J, Volkow ND et al. (1999) Smoking a single cigarette does not produce a measurable reduction in brain MAO B in non-smokers. Nicotine Tob Res 1:325–329
Scott WK, Zhang F, Stajich JM et al. (2005) Family-based case-control study of cigarette smoking and Parkinson disease. Neurology 64(3):442–447
Glassman AH, Helzer JE, Covey LS et al. (1990) Smoking, smoking cessation, and major depression. JAMA 264:1546–1549
Henningfield JE, Clayton R, Pollen W (1990) Involvement of tobacco in alcoholism and illicit drug use. Br J Addict 85:279–292
Hughes JR, Hatsukami DK, Mitchell JE et al. (1986) Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry 143:993–997
George TP, Vessichio JC, Termine A (2003) A preliminary, placebo controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 53:136–143
Khalil AA, Steyn S, Castagnoli N (2000) Isolation and characterization of monoamine oxidase inhibitor from tobacco leaves. Chem Res Toxicol 13:31–35
Castagnoli K, Petzer JB, Steyn SJ, van der Schyf CJ, Castagnoli N Jr. (2003) Inhibition of human MAO-A and MAO-B by a compound isolated from flue-cured tobacco leaves and its neuroprotective properties in the MPTP mouse model of neurodegeneration. Inflammopharmacology 11(2):183–188
Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A Jul;85(14):5274–5278
Schiffer WK, Azmoodeh M, Gerasimov M et al. (2003) Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine. Synapse 48(1):35–38 Apr
Fowler JS, Logan J, Wang GJ et al. (2005) Comparison of monoamine oxidase A in peripheral organs in nonsmokers and smokers. J Nucl Med 46(9):1414–1420
Haass M, Kubler W (1997) Nicotine and sympathetic neurotransmission. Cardiovasc Drugs Ther 10:657–665
Fowler JS, Logan J, Wang GJ et al. (2003) Low monoamine oxidase B in peripheral organs in smokers. Proc Natl Acad Sci U S A 100:11600–11605
Logan J, Fowler JS (2005) Evidence for reduced arterial plasma input, prolonged lung retention and reduced lung monoamine oxidase in smokers. Nucl Med Biol 32:521–529
Rose JE, Behm FM, Westman EC, Coleman RE (1999) Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: Implications for addiction. Drug Alcohol Depend 56:99–107
Evans SM, Cone EJ, Henningfield JE (1996) Arterial and venous cocaine plasma concentrations in humans: Relationship of route of administration, cardiovascular effects and subjective effects. J Pharmacol Exp Ther 279:1345–1356
Simpson GM, Shih JC, Chen K et al. (1999) Schizophrenia, monoamine oxidase and cigarette smoking. Neuropsychopharmacology 20:392–394
Fowler JS, Volkow ND, Wang, GJ, Ding YS, Dewey SL (1999) PET and drug research and development. J Nucl Med 40:1154–1163 Review
Costa-Mallen P, Afsharinejad Z, Kelada SN et al. (2004) DNA sequence analysis of monoamine oxidase B gene coding and promoter regions in Parkinson’s disease cases and unrelated controls. Mov Disord 19:76–83
Adeghate E, Parvez H (2004) The effect of diabetes mellitus on the morphology and physiology of monoamine oxidase in the pancreas. NeuroToxicology 25:167–173
Orlefors H, Sundin A, Fasth KJ et al. (2003) Demonstration of high monoaminoxidase-A levels in neuroendocrine gastroenteropancreatic tumors in vitro and in vivo-tumor visualization using positron emission tomography with 11C-harmine. Nucl Med Biol 30:669–679
Ulus IH, Maher TJ, Wurtman RJ (2000) Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem. Pharmacol. 59:1611–1621
Acknowledgements
This work was supported by the United States Department of Energy (Office of Biological and Environmental Research; DE-AC02-98CH10886) and National Institutes of Health (National Institute for Biomedical Imaging and Bioengineering, EB2630 and National Institute on Drug Abuse, K 05 DA020001 and General Clinical Research Center, MO1RR10710).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fowler, J.S., Logan, J., Volkow, N.D. et al. Translational Neuroimaging: Positron Emission Tomography Studies of Monoamine Oxidase. Mol Imaging Biol 7, 377–387 (2005). https://doi.org/10.1007/s11307-005-0016-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-005-0016-1